Trends in Pharmacological Sciences
Nibbling at CRF receptor control of feeding and gastrocolonic motility
Section snippets
Selective CRF2 receptor ligands
The discovery of endogenous selective CRF2 receptor agonists – the type 2 urocortins (Ucn 2 [9] and Ucn 3 [10]) – opened a new chapter in our understanding of the functional significance of CRF systems in the brain and gut. Because the separate pro-hormones that contain the type 2 urocortins were identified using molecular cloning and database trawling strategies, the existence and structure of the mature peptides remain predicted, rather than known. Evidence 3, 4 favours the 38 amino acid
Satiation-like effects of brain and gut CRF2 receptor activation
In vivo studies with CRF2 receptor ligands suggest an anorectic role for gut CRF2 receptors. The anorectic effects of peripheral Ucn 1, which has been shown to suppress fasting-induced ingestion more potently than does CRF, CCK-8 or leptin [21], were attenuated by intraperitoneal (i.p.) injection of ASVG-30 [21] but not by selective CRF1 receptor antagonists 21, 22. Similarly, i.p. injection of stresscopin and stresscopin-related peptide (CRF2 receptor-selective analogues of Ucn 3 and Ucn 2,
CRF1 versus CRF2 receptor-mediated anorexia
Activation of CRF1 receptors in the brain can suppress feeding independently of CRF2 receptor-mediated mechanisms. For example, selective CRF1 receptor antagonists reverse at least some forms of stress-induced anorexia [26]. CRF1 and CRF2 receptor-mediated anorexia appear to exhibit different time-courses. In rats, i.c.v. administration of CRF1 receptor agonists elicited abbreviated, short-onset anorexia, CRF2 receptor agonists provoked delayed-onset anorexia, and nonselective CRF receptor
Stress inhibits gastric motility via brain and gut CRF2 receptor activation
In addition to their anorectic effects, stressors inhibit gastric motor function in a manner that is reversible by central pretreatment with nonselective CRF receptor antagonists 27, 28. Central administration of nonselective CRF receptor agonists has also been shown to delay gastric meal emptying [27]. Through vagal mechanisms, central infusion of nonselective CRF receptor agonists has been shown to reduce antral gastric motility, inhibit high-amplitude gastric contractions, and shift duodenal
Stress stimulates colonic motility via CRF1 receptor activation
In contrast to the inhibition of gastric motility, diverse stressors stimulate colonic motor function, manifesting as increased colonic motility, decreased colonic transit time, stimulated fecal output and watery diarrhoea. Central and peripheral administration of nonselective or preferential CRF1 27, 28, 35, but not CRF2 28, 32, receptor agonists, produces stress-like effects on colonic activity. Conversely, selective CRF1, but not CRF2, receptor antagonists attenuate stress- 27, 35, 36, 37 or
Physiological relevance of brain and gut CRF2 receptors
Discovered for their hypophysiotropic role in the endocrine stress response, CRF and the CRF1 receptor are commonly viewed as mediators that integrate the organism response to stress, a perspective consistent with the reviewed role of CRF1 receptors in stress-induced stimulation of colonic motility. By association, stress-related properties are often expected for the urocortins and the CRF2 receptor. Figure 3 outlines a proposed framework for understanding the adaptive roles of CRF-related
Acknowledgments
E.P.Z. and G.F.K. were supported by NIH DK26741. Y.T.'s work was supported by NIH DK33061, NIH DK57238 and a VA merit award. We gratefully recognize the editorial assistance of Mike Arends. This is publication number 15648-NP from The Scripps Research Institute.
References (60)
The corticotropin-releasing factor family of peptides and CRF receptors: their roles in the regulation of energy balance
Eur. J. Pharmacol.
(2002)- et al.
The CRF peptide family and their receptors: yet more partners discovered
Trends Pharmacol. Sci.
(2002) - et al.
Distribution of urocortin in the rat's gastrointestinal tract and its colocalization with tyrosine hydroxylase
Peptides
(2002) Design, synthesis and pharmacological characterization of new highly selective CRF2 antagonists: development of 123I-K31440 as a potential SPECT ligand
Peptides
(2002)Secondary structure of antisauvagine analogues is important for CRF receptor antagonism: development of antagonists with increased potency and receptor selectivity
Peptides
(2002)Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide
Brain Res.
(2002)Corticotropin-releasing factor receptor type 1 mediates emotional stress-induced inhibition of food intake and behavioral changes in rats
Brain Res.
(1999)The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist
Bioorg. Med. Chem.
(2000)Fos induction in selective hypothalamic neuroendocrine and medullary nuclei by intravenous injection of urocortin and corticotropin-releasing factor in rats
Brain Res.
(2000)Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats
Gastroenterology
(2000)
Role of CRF receptor 1 in central CRF-induced stimulation of colonic propulsion in rats
Brain Res.
The physiology of corticotropin-releasing hormone deficiency in mice
Peptides
Novel peptide–peptide cooperation may transform feeding behavior
Peptides
Intravenous urocortin II decreases blood pressure through CRF2 receptor in rats
Regul. Pept.
Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat
Brain Res.
Design, synthesis and structure-affinity relationships of 4-methylidenepiperidine and 4-aryl-1,2,3,6-tetrahydropyridine derivatives as corticotropin-releasing factor1 receptor antagonists
Bioorg. Med. Chem.
Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist
Neuropsychopharmacology
Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin
Science
International Union of Pharmacology. XXXVI. current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands
Pharmacol. Rev.
Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor
Nature
Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2
Nat. Genet.
Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF
J. Pharmacol. Exp. Ther.
The role of CRF2 receptors in corticotropin-releasing factor- and urocortin-induced anorexia
NeuroReport
Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors
Proc. Natl. Acad. Sci. U. S. A.
Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor
Proc. Natl. Acad. Sci. U. S. A.
Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor
Nat. Med.
Urocortin III-immunoreactive projections in rat brain: partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression
J. Neurosci.
Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors
J. Comp. Neurol.
The highly selective CRF2 receptor antagonist K41498 binds to presynaptic CRF2 receptors in rat brain
Br. J. Pharmacol.
Potent and long acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists
J. Med. Chem.
Cited by (128)
Hypothalamic mechanism of corticotropin-releasing factor's anorexigenic effect in Japanese quail (Coturnix japonica)
2019, General and Comparative EndocrinologyCitation Excerpt :In the central nervous system, CRF is widely distributed in the paraventricular nucleus (PVN), hippocampus, amygdala and the Barrington’s nucleus (Stengel and Taché, 2014) and has similar distribution pattern in various species (Richard et al., 2004). Treatment with CRF suppresses food intake in various species (Wang et al., 2011; Zorrilla et al., 2003), including chickens (Cline et al., 2009; Denbow et al., 1999; Furuse et al., 1997; Meade and Denbow, 2003; Tachibana et al., 2006), and promotes energy expenditure (Richard et al., 2002). Appetite regulation is a complex system in which central and peripheral signals interact to modify the body’s response to nutrient intake and energy storage and expenditure (Valassi et al., 2008).
Neural Circuitry of Stress, Fear, and Anxiety: Focus on Extended Amygdala Corticotropin-Releasing Factor Systems
2017, Stress: Neuroendocrinology and NeurobiologyUrocortinergic system in the testes of normal and cryptorchid dogs
2016, Annals of AnatomyThe role of the hypothalamus-pituitary-adrenal/interrenal axis in mediating predator-avoidance trade-offs
2016, General and Comparative Endocrinology